Triamcinolone acetonide

Medical uses

Triamcinolone acetonide as an intra-articular injectable has been used to treat a variety of musculoskeletal conditions. When applied to the skin as a topical ointment, it is used to mitigate blistering from poison ivy, oak, and sumac. When combined with nystatin, it is used to treat skin infections with discomfort from fungus, though it should not be used on the eyes. It provides relatively immediate relief and is used before using oral prednisone. Oral and dental paste preparations are used for treating aphthous ulcers.

As an intravitreal injection, triamcinolone acetonide has been used to treat various eye diseases and has been found useful in reducing macular edema. Drug trials have found it to be as efficient as anti-VEGF drugs in eyes with artificial lenses over a two-year period. A systematic review did not find any evidence of any benefit in preventing vision loss in eyes treated with triamcinolone acetonide over placebo, for patients with age-related macular degeneration.

Triamcinolone acetonide is also administered via intralesional injection in the treatment of hypertrophic and keloid scars.

Contraindications

Evidence suggests that usage of triamcinolone acetonide or other steroids to treat macular edema increases the risk of increasing intraocular pressure in patients.

Pharmacology

Pharmacodynamics

Triamcinolone acetonide is a corticosteroid. It is specifically a glucocorticoid, or an agonist of the glucocorticoid receptor, that is about five times as potent as cortisol. It has very little mineralocorticoid effects. The affinities of triamcinolone acetonide for the androgen and estrogen receptors are both

Chemistry

Triamcinolone acetonide, also known as 9α-fluoro-16α-hydroxyprednisolone 16α,17α-acetonide or as 9α-fluoro-11β,16α-17α,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, is a synthetic halogenated cyclic ketal pregnane corticosteroid. It is the C16α,17α acetonide of triamcinolone.

Veterinary use

Triamcinolone acetonide is also used in veterinary medicine as an ingredient in topical ointments and in topical sprays for control of pruritus in dogs. A series of injections with triamcinolone acetonide or another corticosteroid may reduce keloid size and irritation. It is used as a preinductor and/or inductor of birth in cows. It was also used in the horse racing industry, but it is now a banned substance if found in a horse's system on race day.

References

References

1. "KENALOG IN ORABASE triamcinolone acetonide". Australian Government.
2. "KENACORT A10 triamcinolone acetonide". Australian Register of Therapeutic Goods (ARTG).
3. "NASACORT AQ Triamcinolone acetonide". Department of Health and Aged Care, Australian Government.
4. (25 April 2012). "Aristocort C Product information".
5. (25 April 2012). "Nasacort Allergy 24HR Product information".
6. (8 October 2021). "Adcortyl Intra-Articular/Intradermal Injection 10mg/ml - Summary of Product Characteristics (SmPC)".
7. (8 April 2022). "Kenalog Intra-articular / Intramuscular Injection - Summary of Product Characteristics (SmPC)".
8. (1 November 2021). "Nasacort 55 micrograms/dose, nasal spray, suspension - Summary of Product Characteristics (SmPC)".
9. (1 November 2021). "Nasacort Allergy Relief for Adults 55 micrograms/dose, nasal spray, suspension - Summary of Product Characteristics (SmPC)".
10. "Xipere- triamcinolone acetonide injection, suspension".
11. (8 March 2018). "Active substance(s): triamcinolone (topical and nasal formulations)". European Medicines Agency.
12. "Triamcinolone Topical".
13. (3 February 2014). "Nasacort Allergy 24HR- triamcinolone acetonide spray, metered".
14. (3 March 2023). "Competitive Generic Therapy Approvals".
15. "Nystatin And Triamcinolone (Topical Route)". Mayo Foundation for Medical Education and Research.
16. (November 2020). "Intravitreal steroids for macular edema in diabetes". The Cochrane Database of Systematic Reviews.
17. (January 2013). "Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews.
18. (2008). "Intralesional Steroid Therapy (Patient Information Leaflets)".
19. (September 1966). "The treatment of keloids with triamcinolone acetonide". Plastic and Reconstructive Surgery.
20. (September 2015). "Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion". The Cochrane Database of Systematic Reviews.
21. (2004). "Arzneistoff-Profile". Govi Pharmazeutischer Verlag.
22. (6 December 2012). "Drug Toxicity in Embryonic Development II: Advances in Understanding Mechanisms of Birth Defects: Mechanistics Understanding of Human Development Toxicants". Springer Science & Business Media.
23. (March 2017). "Corticosteroid Injections: A Review of Sex-Related Side Effects". Orthopedics.
24. (January 1978). "The mechanism of ovulation inhibition by triamcinolone acetonide". The Journal of Clinical Endocrinology and Metabolism.
25. (1982). "In vitro and ex vivo binding to uterine progestin receptors of the rat as a tool to assay progestational activity of glucocorticoids". Methods and Findings in Experimental and Clinical Pharmacology.
26. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
27. [http://www.virbacvet.com/pdf/product_pdfs/GENESIS_Topical_Spray_insert.pdf Genesis (triamcinolone acetonide) Topical Spray] Drug information
28. [https://www.racingpost.com/news/news/champion-hurdle-favourite-yanworth-failed-drug-test/291782 Champion Hurdle favorite Yanworth failed drug test]